Wuxi Jiyu Shanhe Pharmaceutical Technology

Wuxi Jiyu Shanhe Pharmaceutical Technology is a Chinese biotechnology company focused on the development of next-generation small molecule drugs using targeted protein degradation (TPD) technologies. The company specializes in the discovery of molecular glues and PROTACs (Proteolysis-Targeting Chimeras) to modulate proteins previously considered undruggable. Founded in 2021 and headquartered in Wuxi, the firm leverages its proprietary discovery platform to advance a pipeline primarily targeting oncology and immunological disorders. Jiyu Shanhe has successfully secured early-stage venture capital, including an angel round from investors such as InnoPinnacle Fund, to support its research and development efforts. The company's leadership includes experts with significant experience in medicinal chemistry and drug discovery from major global and domestic pharmaceutical organizations. Its current operations are centered on pre-clinical validation of lead candidates aimed at treating various cancers.